Daiwa Securities Group’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-176
| Closed | -$9K | – | 1416 |
|
|
2025
Q4 | $9K | Hold |
176
| – | – | ﹤0.01% | 1195 |
|
|
2025
Q3 | $8K | Sell |
176
-33
| -16% | -$1.33K | ﹤0.01% | 1173 |
|
|
2025
Q2 | $7K | Hold |
209
| – | – | ﹤0.01% | 1137 |
|
|
2025
Q1 | $7K | Hold |
209
| – | – | ﹤0.01% | 1115 |
|
|
2024
Q4 | $8K | Hold |
209
| – | – | ﹤0.01% | 1136 |
|
|
2024
Q3 | $7K | Buy |
209
+52
| +33% | +$1.62K | ﹤0.01% | 1153 |
|
|
2024
Q2 | $4K | Sell |
157
-60
| -28% | -$1.74K | ﹤0.01% | 1217 |
|
|
2024
Q1 | $7K | Hold |
217
| – | – | ﹤0.01% | 1189 |
|
|
2023
Q4 | $6K | Hold |
217
| – | – | ﹤0.01% | 1198 |
|
|
2023
Q3 | $6K | Hold |
217
| – | – | ﹤0.01% | 1147 |
|
|
2023
Q2 | $7K | Hold |
217
| – | – | ﹤0.01% | 1159 |
|
|
2023
Q1 | $8K | Hold |
217
| – | – | ﹤0.01% | 1127 |
|
|
2022
Q4 | $8K | Buy |
217
+35
| +19% | +$1.22K | ﹤0.01% | 1127 |
|
|
2022
Q3 | $6K | Hold |
182
| – | – | ﹤0.01% | 1156 |
|
|
2022
Q2 | $5K | Hold |
182
| – | – | ﹤0.01% | 1174 |
|
|
2022
Q1 | $6K | Hold |
182
| – | – | ﹤0.01% | 1165 |
|
|
2021
Q4 | $5K | Hold |
182
| – | – | ﹤0.01% | 1204 |
|
|
2021
Q3 | $5K | Buy |
182
+83
| +84% | +$2.23K | ﹤0.01% | 1182 |
|
|
2021
Q2 | $3K | Hold |
99
| – | – | ﹤0.01% | 1120 |
|
|
2021
Q1 | $3K | Hold |
99
| – | – | ﹤0.01% | 1121 |
|
|
2020
Q4 | $2K | Sell |
99
-197
| -67% | -$4.24K | ﹤0.01% | 1140 |
|
|
2020
Q3 | $6K | Hold |
296
| – | – | ﹤0.01% | 1080 |
|
|
2020
Q2 | $5K | Hold |
296
| – | – | ﹤0.01% | 1108 |
|
|
2020
Q1 | $5K | Hold |
296
| – | – | ﹤0.01% | 1103 |
|
|
2019
Q4 | $7K | Sell |
296
-36
| -11% | -$874 | ﹤0.01% | 1088 |
|
|
2019
Q3 | $9K | Hold |
332
| – | – | ﹤0.01% | 1040 |
|
|
2019
Q2 | $11K | Hold |
332
| – | – | ﹤0.01% | 1052 |
|
|
2019
Q1 | $12K | Buy |
332
+49
| +17% | +$1.82K | ﹤0.01% | 1026 |
|
|
2018
Q4 | $9K | Hold |
283
| – | – | ﹤0.01% | 1005 |
|
|
2018
Q3 | $14K | Hold |
283
| – | – | ﹤0.01% | 1014 |
|
|
2018
Q2 | $17K | Sell |
283
-68,700
| -100% | -$3.56M | ﹤0.01% | 1018 |
|
|
2018
Q1 | $3.16M | Buy |
+68,983
| New | +$2.88M | 0.03% | 299 |
|
Other funds holding SUPN
NAMI
AC
Daiwa Securities Group's SUPN Position: Q1 2026 in Review
Daiwa Securities Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 176 shares — an estimated $9K sold.
Daiwa Securities Group first reported a position in SUPN in Q1 2018 and held it in 32 quarters. The position peaked at $3.16M in Q1 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Daiwa Securities Group reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 176 Supernus Pharmaceuticals shares in Q1 2026, an estimated $9K.
- Daiwa Securities Group first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's Supernus Pharmaceuticals position peaked at $3.16M in Q1 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.